MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
13.49
+0.10 (0.75%)
At close: Dec 22, 2025, 4:00 PM EST
13.45
-0.04 (-0.30%)
After-hours: Dec 22, 2025, 4:13 PM EST
MLTX Employees
MoonLake Immunotherapeutics had 100 employees as of December 31, 2024. The number of employees increased by 50 or 100.00% compared to the previous year.
Employees
100
Change (1Y)
50
Growth (1Y)
100.00%
Revenue / Employee
n/a
Profits / Employee
-$2,104,955
Market Cap
962.83M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 100 | 50 | 100.00% |
| Dec 31, 2023 | 50 | 30 | 150.00% |
| Dec 31, 2022 | 20 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MLTX News
- 7 days ago - MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm - GlobeNewsWire
- 11 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - GlobeNewsWire
- 11 days ago - DEADLINE NEXT WEEK: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Contact the Firm Before December 15, 2025 - PRNewsWire
- 14 days ago - MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Newsfile Corp
- 14 days ago - Stock Picks From Seeking Alpha's November 2025 New Analysts - Seeking Alpha
- 17 days ago - MoonLake Immunotherapeutics (MLTX) Investors are Encouraged to Act before the Upcoming December 15 Securities Fraud Deadline – Contact BFA Law if You Lost Money - GlobeNewsWire
- 17 days ago - MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman - PRNewsWire
- 18 days ago - MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority - GlobeNewsWire